header logo image


Page 249«..1020..248249250251..260270..»

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

January 12th, 2021 3:53 am

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Follow this link:
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Read More...

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

January 12th, 2021 3:53 am

Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

Continue reading here:
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Read More...

INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

January 12th, 2021 3:53 am

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021.

Here is the original post:
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

Read More...

Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

January 12th, 2021 3:53 am

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials have been lodged with the ASX, and Mesoblast’s presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference can be accessed at https://journey.ct.events/view/f353f7fd-772e-43aa-aab0-e959da38254d. An archived webcast of the conference presentation will be available for 90 days on the Company’s website at www.mesoblast.com.

Link:
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

Read More...

Generation Bio Announces Closing of Public Offering

January 12th, 2021 3:53 am

Continue reading here:
Generation Bio Announces Closing of Public Offering

Read More...

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

January 12th, 2021 3:53 am

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

Here is the original post:
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Read More...

T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

January 12th, 2021 3:53 am

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

Read more:
T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

Read More...

Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

January 12th, 2021 3:53 am

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Read the original here:
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

Read More...

Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

January 12th, 2021 3:53 am

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on January 12, 2021 under the ticker symbol “QLI”.

Read the original post:
Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

Read More...

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

January 12th, 2021 3:53 am

- Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma

Go here to see the original:
Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

Read More...

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common…

January 12th, 2021 3:53 am

Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

View post:
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common...

Read More...

Addex to Present at the Baader Helvea Swiss Equities Conference

January 12th, 2021 3:53 am

Geneva, Switzerland, January 12, 2021 -  Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 – January 15, 2021.

Read the original post:
Addex to Present at the Baader Helvea Swiss Equities Conference

Read More...

Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

January 12th, 2021 3:53 am

REGULATED INFORMATION

Go here to see the original:
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

Read More...

iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

January 12th, 2021 3:53 am

PRESS RELEASE

See the original post:
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

Read More...

BetterLife Provides Shareholder Update and 2021 Product Development Roadmap

January 12th, 2021 3:53 am

VANCOUVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- VANCOUVER, January 12, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to provide an overview of the Company’s primary plans for this calendar year to develop 3 novel therapeutic products, each addressing significant unmet needs with multi-billion dollar market potential.

See the article here:
BetterLife Provides Shareholder Update and 2021 Product Development Roadmap

Read More...

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

January 12th, 2021 3:53 am

SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.

See more here:
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

Read More...

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

January 12th, 2021 3:53 am

ORION CORPORATION  STOCK EXCHANGE RELEASE 12 JANUARY 2021 at 10.15 EET

Continue reading here:
Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

Read More...

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

January 12th, 2021 3:53 am

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Visit link:
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Read More...

Poland’s defense minister: COVID-19 is forcing the military to reexamine its role – DefenseNews.com

January 12th, 2021 3:53 am

Without a doubt, 2020 will be recorded in history with the theme of COVID-19. The pandemic heavily affected our lives, creating new global challenges in almost all spheres, including security and defense. While the new normal is reshaping our reality, the existing security threats have not disappeared. It gives a reason to enhance our cooperation and develop a flexible approach more than any time before.

The outbreak has consequently led to a thorough examination of the armed forces role in countering this unprecedented crisis resulting from the spread of the virus.

Since the beginning, the Polish Armed Forces have been actively engaged in supporting civilian authorities and the health care system. Every day, an average of about 10,000 soldiers were actively fighting the pandemic, and another 10,000 were on standby. Fourteen military hospitals, five medical preventative medicine centers, and the Military Institute of Hygiene and Epidemiology are constantly providing support to the national health care system. Soldiers were collecting around 55 thousand swabs each week and were supported almost 700 hospitals, 173 sanitary-epidemiological stations, and about 11,000 combatants, veterans, seniors and medical staff families. Soldiers are also supporting construction of 17 temporary hospitals, have built over 50 isolation centers and have operated over 20 field-admission points.

In this demanding period, the Polish Territorial Defence Forces the relatively young fifth service of the Polish Armed Forces have impeccably proved their importance and effectiveness.

At the same time, Poland has been a part of numerous activities on the international level. NATO is using its existing mechanisms and bodies, such as the Euro-Atlantic Disaster Response Coordination Center and strategic airlift programs, to support allies. It has also developed new tools such as new operations plans and a trust fund to strengthen response capabilities. NATO members provide mutual assistance to each other by donating vital medical equipment and relief material. These actions are a visible proof of international solidarity in response to this extraordinary multidimensional challenge we face nowadays. They also constitute valuable lessons learned to be implemented to be better prepared and resilient for similar challenges in the future.

We realized that without exchanging experience, our efforts would not be so efficient. Therefore, in spring 2020, our Military Institute of Medicine led several medical missions to Italy, the United States and Slovenia. Our experts had a unique opportunity to share best practices and obtain knowledge that could be applied to design national response measures.

Regardless of our fight against COVID-19, effective deterrence and defense remain the core task of our armed forces. Therefore, throughout 2020 we made every effort to fulfill previously planned activities and goals. Several top exercises such as Defender Europe 2020, conducted in a highly sanitary regime, proved allied determination to sustain high readiness of its forces.

Sign up for our Early Bird Brief Get the defense industry's most comprehensive news and information straight to your inbox

Subscribe

Enter a valid email address (please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Thanks for signing up!

By giving us your email, you are opting in to the Early Bird Brief.

The COVID-19 pandemic will most likely have an impact on national security policies, including defense budgets, but we remain committed to keeping out defense spending above the required 2 percent of gross domestic product.

On the national level, Poland continues to strengthen its defense potential through further development of the Polish Armed Forces and their modernization.

We intend to keep up international cooperation aimed at increasing defense capabilities, specifically contributing to the needs of the alliance and the European Union. In this respect, we will implement state-of-the-art equipment, such as the F-35 fighter jet, the Patriot missile defense system and the High Mobility Artillery Rocket System.

Where applicable, we will engage our national defense industry in modernization projects to include procurement of self-propelled howitzers and mortars.

As before, close international collaboration aimed at meeting key commitments and pledges will be of the utmost importance. Despite the negative effects that COVID-19 may bring to our economies, Poland will maintain its involvement in allied missions, operations and initiatives in line with the 360-degree approach applying to NATOs eastern flank and other strategic directions. It translates to our constant engagement in the Enhanced Forward Presence in Latvia, the Tailored Forward Presence in Romania and the Baltic Air Policing mission, as well as in peacekeeping activities in the Western Balkans. We will continue to declare significant forces to the Very High Readiness Joint Task Force, NATO Response Force and NATO Readiness Initiative, not to mention our support to the international community in the fight against terrorism.

The COVID-19 pandemic proves that stronger cooperation in security is needed, though some may raise the argument that with the public health challenges we confront every day, defense expenditures are secondary. Nevertheless, as we are responsible for building a security landscape for the coming decades, we must concentrate on common defense projects and put emphasis on solidarity.

Mariusz Blaszczak is Polands minister of defense.

Continued here:
Poland's defense minister: COVID-19 is forcing the military to reexamine its role - DefenseNews.com

Read More...

Dr. Russell Surasky Helping Others Understand Opioid Addiction and the La – The Jerusalem Post

January 12th, 2021 3:53 am

Understanding how opiates work is something that most people are not that well-educated about. This poses a major problem, given that the United States has some of the highest opiate abuse rates in the world. Every hour, over five people die due to drug overdoses within the US. The first step in reducing opiate addiction rates is to educate people on how opioids work and how they lead to a high level of addiction seldom seen.Dr. Russell Surasky is someone who has become an expert on opiate addiction. He is triple board-certified in neurology, addiction medicine, and preventative medicine. Dr. Surasky is the medical director of Bridge Back to Life, which is a multi-center outpatient addiction treatment program that helps those addicted to dangerous opiates like fentanyl. He has also founded the Surasky Neurological Center for Addiction in Great Neck, NY.Dr. Surasky believes that once someone understands how opioids work, they will also realize why it is incredibly difficult for someone addicted to them to stop cold turkey. Rather than being a moral failing, as politicians have been telling us for decades, addiction is a complex chronic disease that includes a lifetime risk of relapse. Thankfully, there have been advances in our understanding of the brain and how opiates affect it. There are now treatments, which Dr. Surasky uses, that have the power to reverse the neurological damage caused by opiates, leading to a permanent recovery.The first step in understanding opioid addiction is to understand what opioids are themselves. Generally, the word opioid refers to drugs that originate from the opium poppy. These include morphine, codeine, heroin, fentanyl, and others. Synthetic drugs like Oxycodone and Hydrocodone, known as Percocet and Vicodin, are also classified as opioids. The way they work is by lighting up the opiate receptors in the brain and spinal cord. These opioids have the power to significantly reduce the amount of pain someone feels. However, opiate receptors will also play into how we feel, both mentally and emotionally. That leads to opioids temporarily improving someones well-being. In fact, they will drastically lower feelings of depression and anxiety in the user, but only temporarily.Opioids that get prescribed to mitigate pain can indeed provide pain relief. However, they do so at a cost. It is very easy to misuse them and get hooked on them. That is due to these drugs overstimulating the brain's reward system. There is a euphoria experienced when using opioids that, once gone, turns to depression.As soon as the drug wears off, it will detach from the opiate receptors it was locked into, which tells the brain that it needs more. Thankfully, there are safe and non-addictive methods today that can effectively wean people off of opiates, including Vivitrol and spinal adjustments, among others.

Original post:
Dr. Russell Surasky Helping Others Understand Opioid Addiction and the La - The Jerusalem Post

Read More...

Page 249«..1020..248249250251..260270..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick